Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children with metastatic rhabdomyosarcoma or other malignant mesenchymal tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Societe Internationale d'Oncologie Pediatrique
• Collaborators: Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique
• Treatments: Carboplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Etoposide; Ifosfamide; Liposomal doxorubicin; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic rhabdomyosarcoma or other malignant mesenchymal tumors

• Standard risk defined as:

• Less than 10 years of age

• No bone or bone marrow involvement

• High risk defined as:

• At least 10 years of age OR

• Bone or bone marrow involvement

• Diagnosed less than 8 weeks ago

• Previously untreated disease except for initial surgery within the past 8 weeks

PATIENT CHARACTERISTICS:

Age:

• 6 months to under 18 years

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior biologic therapy

Chemotherapy:

• No prior chemotherapy

Endocrine therapy:

• No prior endocrine therapy

Radiotherapy:

• Concurrent radiotherapy allowed

Surgery:

• See Disease Characteristics